Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study
The DOI matches its Crossref record; 61 of the 63 references it cites were found in a registry or an index.
Abstract
Background and Aims: Faecal biomarkers, particularly calprotectin [FCAL], have become important diagnostic and monitoring tools in inflammatory bowel diseases [IBD]. As FCAL is mainly produced by neutrophils, we hypothesised that faecal lipocalin-2 [FLCN2], also expressed by intestinal epithelial cells [IEC], could be beneficial in specific clinical situations. Methods: We compared clinical and endoscopic activity-related correlations between FCAL and FLCN2, assayed from the same sample, in a cohort of 132 patients (72 Crohn’s disease [CD]) and 40 controls. A detailed analysis of cellular origins was done by confocal microscopy and flow cytometry. To evaluate the potential to detect low-grade inflammation, we studied faecal and tissue concentrations in a cohort with clinical, endoscopic, and histological remission. Results: There was an excellent correlation between FCAL and FLCN2 [rS = 0.87, p <0.001] and comparable sensitivity and specificity to predict clinical and endoscopic disease activity, with optimal thresholds for endoscopic activity of 73.4 and 1.98 µg/g in ulcerative colitis [UC] and 78.4 and 0.56 µg/g in Crohn’s disease for FCAL and FLCN2, respectively. Strong co-expression of both proteins was observed in granulocytes and macrophages. IECs expressed LCN2 but not CAL. In our IBD cohort in deep remission neither FCAL nor FLCN2 was different from controls; yet mucosal LCN2 but not CAL expressions remained elevated in the rectum of UC and the ileum of CD patients. Conclusions: This study corroborates the diagnostic equivalence of FLCN2 and FCAL in IBD. In remission, persistent mucosal overexpression renders LCN2 an attractive candidate for molecular inflammation warranting further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Current clinical proxies for dysbiosis include MAdCAM-1, REG3, calprotectin, and lipocalin-2 in fecal samples.52,157,158”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [157]
Citations
Cites
Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., Benchimol, E. I., Panaccione, R., Ghosh, S., Barkema, H. W., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.001 · Cited by 4,833
Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L., & Colombel, J.-F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32126-2 · Cited by 3,531
Satsangi, J., Silverberg, M. S., Vermeire, S., & Colombel, J.-F. (2006) · Gut · doi:10.1136/gut.2005.082909 · Cited by 3,176
Ford Alexander, C., Paul, M., Hanauer Steven, B., 谭蓓, & Dong, W. Z. (2001) · Cited by 3,020
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,959
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy113 · Cited by 1,823
Kaser, A., Zeissig, S., & Blumberg, R. S. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101225 · Cited by 1,806
Daperno, M., D'Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., et al. (2004) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)01878-4 · Cited by 1,774
Kaser, A., Lee, A.-H., Franke, A., Glickman, J. N., Zeissig, S., Tilg, H., Nieuwenhuis, E. E. S., Higgins, D. E., Schreiber, S., Glimcher, L. H., et al. (2008) · Cell · doi:10.1016/j.cell.2008.07.021 · Cited by 1,411
Self-citationGoetz, D. H., Holmes, M. A., Borregaard, N., Bluhm, M. E., Raymond, K. N., & Strong, R. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00708-6 · Cited by 1,355
Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase
Kjeldsen, L., Johnsen, A. H., Sengeløv, H., & Borregaard, N. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82217-7 · Cited by 1,284
The burden of inflammatory bowel disease in Europe
Burisch, J., Jess, T., Martinato, M., & Lakatos, P. L. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.01.010 · Cited by 961
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis
Geboes, K. (2000) · Gut · doi:10.1136/gut.47.3.404 · Cited by 943
D'Haens, G. R., Geboes, K., Peeters, M., Baert, F., Penninckx, F., & Rutgeerts, P. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70476-7 · Cited by 868
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
DʼHaens, G., Ferrante, M., Vermeire, S., Baert, F., Noman, M., Moortgat, L., Geens, P., Iwens, D., Aerden, I., Van Assche, G., et al. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22917 · Cited by 816
Mosli, M. H., Zou, G., Garg, S. K., Feagan, S. G., MacDonald, J. K., Chande, N., Sandborn, W. J., & Feagan, B. G. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.120 · Cited by 690
Louis, E., Mary, J., Vernier–Massouille, G., Grimaud, J., Bouhnik, Y., Laharie, D., Dupas, J., Pillant, H., Picon, L., Veyrac, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.09.034 · Cited by 597
Chassaing, B., Srinivasan, G., Delgado, M. A., Young, A. N., Gewirtz, A. T., & Vijay-Kumar, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044328 · Cited by 554
Chakraborty, S., Kaur, S., Guha, S., & Batra, S. K. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.008 · Cited by 503
An Update on Inflammatory Bowel Disease
Sairenji, T., Collins, K. L., & Evans, D. V. (2017) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2017.07.010 · Cited by 499
Calprotectin – a pleiotropic molecule in acute and chronic inflammation.
Stříž, I., & Trebichavský, I. (2004) · Physiological Research · doi:10.33549/physiolres.930448 · Cited by 466
Extraintestinal manifestations of inflammatory bowel disease.
LEVINE, J. S., & Burakoff, R. B. (2011) · Europe PMC (PubMed Central) · Cited by 427
Lipocalin 2: an emerging player in iron homeostasis and inflammation
Xiao, X., Yeoh, B. S., & Vijay-Kumar, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064559 · Cited by 426
Nielsen, B. S., Borregaard, N., Bundgaard, J. R., Timshel, S., Sehested, M., & Kjeldsen, L. (1996) · Gut · doi:10.1136/gut.38.3.414 · Cited by 421
Henriksen, M., Jahnsen, J., Lygren, I., Stray, N., Sauar, J., Vatn, M. H., Moum, B., & and the IBSEN Study Group (2008) · Gut · doi:10.1136/gut.2007.146357 · Cited by 420
Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy
von Roon, A. C., Karamountzos, L., Purkayastha, S., Reese, G. E., Darzi, A. W., Teare, J. P., Paraskeva, P., & Tekkis, P. P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01126.x · Cited by 401
Lipocalin 2 protects from inflammation and Tumorigenesis associated with gut microbiota alterations
Moschen, A. R., Gerner, R. R., Wang, J., Klepsch, V., Adolph, T. E., Reider, S. J., Hackl, H., Pfister, A., Schilling, J., Moser, P. L., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.03.007 · Cited by 375
Self-citationExtraintestinal manifestations in inflammatory bowel disease
Danese, S. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i46.7227 · Cited by 373
The Cytokine IL-22 Promotes Pathogen Colonization by Suppressing Related Commensal Bacteria
Behnsen, J., Jellbauer, S., Wong, C. P., Edwards, R. A., George, M. D., Ouyang, W., & Raffatellu, M. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.003 · Cited by 282
Korndörfer, I. P., Brueckner, F., & Skerra, A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.04.065 · Cited by 276
Skerra, A. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(00)00145-x · Cited by 217
Lasson, A., Stotzer, P.-O., Öhman, L., Isaksson, S., Sapnara, M., & Strid, H. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.06.002 · Cited by 211
Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease
Okamoto, R., & Watanabe, M. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-015-1098-4 · Cited by 205
New treatment options for inflammatory bowel diseases
Verstockt, B., Ferrante, M., Vermeire, S., & Van Assche, G. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1449-z · Cited by 170
Zittan, E., Kelly, O. B., Kirsch, R., Milgrom, R., Burns, J., Nguyen, G. C., Croitoru, K., Van Assche, G., Silverberg, M. S., & Steinhart, A. H. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000652 · Cited by 167
Mucosal Healing in Ulcerative Colitis: A Comprehensive Review
Boal Carvalho, P., & Cotter, J. (2017) · Drugs · doi:10.1007/s40265-016-0676-y · Cited by 164
Guardiola, J., Lobatón, T., Alonso, L. R., Ruiz‐Cerulla, A., Aràjol, C., Loayza, C., Sanjuán, X., Sánchez, E., & Rodríguez‐Moranta, F. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.06.020 · Cited by 144
Stallhofer, J., Friedrich, M., Konrad-Zerna, A., Wetzke, M., Lohse, P., Glas, J., Tillack-Schreiber, C., Schnitzler, F., Beigel, F., & Brand, S. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000515 · Cited by 130
Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease
Sipponen, T., & Kolho, K.-L. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2014.987809 · Cited by 125
Takashima, S., Kato, J., Hiraoka, S., Nakarai, A., Takei, D., Inokuchi, T., Sugihara, Y., Takahara, M., Harada, K., Okada, H., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.66 · Cited by 117
Singh, V., Yeoh, B. S., Chassaing, B., Zhang, B., Saha, P., Xiao, X., Awasthi, D., Shashidharamurthy, R., Dikshit, M., Gewirtz, A., et al. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.03.007 · Cited by 117
Fecal calprotectin in inflammatory bowel diseases: update and perspectives
Manceau, H., Chicha-Cattoir, V., Puy, H., & Peoc’h, K. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0522 · Cited by 112
Age-Dependent Variations in Fecal Calprotectin Concentrations in Children
Rugtveit, J., & Fagerhol, M. K. (2002) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200203000-00022 · Cited by 111
Mooiweer, E., Severs, M., Schipper, M. E. I., Fidder, H. H., Siersema, P. D., Laheij, R. J. F., & Oldenburg, B. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jju003 · Cited by 110
Fecal neutrophil gelatinase‐associated lipocalin as a biomarker for inflammatory bowel disease
Thorsvik, S., Damås, J. K., Granlund, A. V., Flo, T. H., Bergh, K., Østvik, A. E., & Sandvik, A. K. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13598 · Cited by 100
Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis
Osterman, M. T., Aberra, F. N., Cross, R., Liakos, S., McCabe, R., Shafran, I., Wolf, D., Hardi, R., Nessel, L., Brensinger, C., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.03.035 · Cited by 93
Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease
Ikhtaire, S., Shajib, M. S., Reinisch, W., & Khan, W. I. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1182-4 · Cited by 88
Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis
Patel, A., Panchal, H., & Dubinsky, M. C. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001157 · Cited by 83
Husebye, E., Tøn, H., & Johne, B. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.04126.x · Cited by 79
Schlehuber, S., & Skerra, A. (2002) · Biophysical Chemistry · doi:10.1016/s0301-4622(02)00026-1 · Cited by 70
Lee, S.-H., Kim, M.-J., Chang, K., Song, E. M., Hwang, S. W., Park, S. H., Yang, D., Kim, K., Byeon, J., Myung, S., et al. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0669-7 · Cited by 65
de Bruyn, M., Arijs, I., De Hertogh, G., Ferrante, M., Van Assche, G., Rutgeerts, P., Vermeire, S., & Opdenakker, G. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv148 · Cited by 61
Stawczyk‐Eder, K., Eder, P., Łykowska‐Szuber, L., Krela‐Kaźmierczak, I., Klimczak, K., Szymczak‐Tomczak, A., Szachta, P., Katulska, K., & Linke, K. (2015) · Archives of Medical Science · doi:10.5114/aoms.2014.43672 · Cited by 60
Chapter 4 Urinary Biomarkers for the Detection of Renal Injury
Rosner, M. H. (2009) · Advances in clinical chemistry · doi:10.1016/s0065-2423(09)49004-8 · Cited by 56
de Bruyn, M., Arijs, I., Wollants, W., Machiels, K., van Steen, K., Assche, G. V., Ferrante, M., Rutgeerts, P., Vermeire, S., & Opdenakker, G. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000068 · Cited by 55
Expression of neutrophil gelatinase-associated lipocalin (NGAL) in the gut in Crohn’s disease
Thorsvik, S., Bakke, I., van Beelen Granlund, A., Røyset, E. S., Damås, J. K., Østvik, A. E., & Sandvik, A. K. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2860-8 · Cited by 54
Limited uptake of ulcerative colitis “treat‐to‐target” recommendations in real‐world practice
Bryant, R. V., Costello, S. P., Schoeman, S., Sathananthan, D., Knight, E., Lau, S. Y., Schoeman, M., Mountifield, R. E., Tee, D., Travis, S. P. L., et al. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13923 · Cited by 45
Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature
Darr, U., & Khan, N. H. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0130-6 · Cited by 40
Treat to Target in Inflammatory Bowel Disease
Bossuyt, P. J., & Vermeire, S. (2016) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-016-0077-z · Cited by 35
Peyrin‐Biroulet, L., Feagan, B. G., Mansfield, J. C., Rubin, D. T., Arulmani, U., Maciuca, R. D., Tyrrell, H. E. J., Thommes, J. A., & Tole, S. (2017) · Gastroenterology · doi:10.1016/s0016-5085(17)32152-2 · Cited by 4
Cited by
Calprotectin: from biomarker to biological function
Jukic, A., Bakiri, L., Wagner, E. F., Tilg, H., & Adolph, T. E. (2021) · Gut · doi:10.1136/gutjnl-2021-324855 · Cited by 500
Self-citationThe Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability
Schoultz, I., & Keita, Å. V. (2020) · Cells · doi:10.3390/cells9081909 · Cited by 467
Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases
Zollner, A., Koch, R., Jukic, A., Pfister, A., Meyer, M., Rössler, A., Kimpel, J., Adolph, T. E., & Tilg, H. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.04.037 · Cited by 307
“To decipher SARS-CoV-2 RNA persistence in the gastrointestinal tract, we isolated RNA as described previously.(17) In”
Self-citationBacteroidetes Species Are Correlated with Disease Activity in Ulcerative Colitis
Nomura, K., Ishikawa, D., Okahara, K., Ito, S., Haga, K., Takahashi, M., Arakawa, A., Shibuya, T., Osada, T., Kuwahara-Arai, K., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081749 · Cited by 150
Hajjar, R., González, E., Fragoso, G., Oliero, M., Alaoui, A. A., Calvé, A., Rendos, H. V., Djediai, S., Cuisiniere, T., Laplante, P., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-328389 · Cited by 139
Metadata
- Authors
- Zollner, A., Schmiderer, A., Reider, S. J., Oberhuber, G., Pfister, A., Texler, B., Watschinger, C., Koch, R., Effenberger, M., Raine, T., Tilg, H., & Moschen, A. R.
- Affiliations
- Innsbruck Medical University (AT)
- Tirol Kliniken (AT)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Corresponding author
- Moschen, Alexander R
- ORCID
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-06-18
- Volume
- 15
- Issue
- 1
- Pages
- 43-54
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W3035770450
- Cited by
- 95
- References
- 63
- Citations by year
- 2026: 16 · 2025: 23 · 2024: 16 · 2023: 20 · 2022: 11 · 2021: 6 · 2020: 3
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Crohn s and Colitis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- independent general research (55130045)
- Christian Doppler Research Association,
- Austrian Federal Ministry of Science, Research, and Economy and the National Foundation for Research, Technology, and Development
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- fecal calprotectin
- MeSH terms
- Lipocalin-2, Colitis, Ulcerative, Colonoscopy, Crohn Disease, Feces, Female, Humans, Ileum, Inflammation, Intestinal Mucosa, Male, Rectum, Remission Induction, Sensitivity and Specificity, Severity of Illness Index, Biomarkers, Gene Expression Profiling, Leukocyte L1 Antigen Complex
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.